Public market insider buying at BELLUS Health (BLU)

Public market insider buying at BELLUS Health (T:BLU)

Orbimed Advisors, a 10% Holder, acquired 1,462,700 Common Shares on a control or direction basis for registered holder OrbiMed Private Investments VII, LP at prices ranging from $1.230 to $1.420 between May 7th, 2019 and May 10th, 2019. This represents a $1,897,652 investment into the company's shares and an account share holdings change of 6.9%.

BELLUS Health is in the Pharmaceuticals Sub Industry Group under the Healthcare Sector.

BELLUS Health Inc is a Canada-based biopharmaceutical development company. The Company's pipeline of projects includes the BLU-5937 for chronic cough and several other partnered clinical-stage drug development programs. BLU-5937 is a potent, selective, orally bio-available small molecule antagonist of the P2X3 receptor, a clinically validated target for chronic cough. BLU-5937 has the potential to help a number of chronic cough patients who do not respond to current therapies. BELLUS Health Inc also has economic interests in other partnered clinical-stage drug development programs, including KIACTA for sarcoidosis, AMO-01 for Fragile X Syndrome and ALZ-801 for APOE4 homozygous Alzheimer's disease.